{
    "2019-07-11": [
        [
            {
                "time": "",
                "original_text": "科伦药业创仿结合发力自主研发药物制剂业务销售或超百亿",
                "features": {
                    "keywords": [
                        "科伦药业",
                        "创仿结合",
                        "自主研发",
                        "药物制剂",
                        "销售"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "第二批“4+7”带量采购如箭在弦，我们做了这6点猜想",
                "features": {
                    "keywords": [
                        "4+7",
                        "带量采购",
                        "政策",
                        "猜想"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞470名！20家药企入围2019年中国500强排行榜！",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "中国500强",
                        "排名"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "[\"科\"公司峰会]恒瑞医药研发人少费用多药明康德反之",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "研发",
                        "费用",
                        "药明康德"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "北上资金今日买入招商银行超3亿元",
                "features": {
                    "keywords": [
                        "北上资金",
                        "招商银行",
                        "买入"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "金融"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医疗保健：坚持投资主线 荐11股",
                "features": {
                    "keywords": [
                        "医疗保健",
                        "投资主线",
                        "荐股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医疗保健"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "科创板大幕正徐徐拉开，成长板块估值或提升 关注两大投资方向",
                "features": {
                    "keywords": [
                        "科创板",
                        "成长板块",
                        "估值",
                        "投资方向"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技",
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "医药板块小幅走高 天目药业兴齐眼药等涨停",
                "features": {
                    "keywords": [
                        "医药板块",
                        "走高",
                        "天目药业",
                        "兴齐眼药",
                        "涨停"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "西南证券：科创板的大幕会如何拉开",
                "features": {
                    "keywords": [
                        "西南证券",
                        "科创板",
                        "大幕"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "2019年上半年91个药品入选 新药申请超50%",
                "features": {
                    "keywords": [
                        "2019年",
                        "药品",
                        "新药申请",
                        "入选"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "当心“伪白马股”爆雷",
                "features": {
                    "keywords": [
                        "伪白马股",
                        "爆雷"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "全行业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "恒瑞医药:抗肿瘤重磅首仿获批,持续完善肿瘤产品",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "抗肿瘤",
                        "首仿",
                        "获批",
                        "肿瘤产品"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "制药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}